Mouse Anti-CRYAB Recombinant Antibody (CBT389) (V2LY-0625-LY3563)



Basic Information
Application | Note |
ELISA | 1:10,000 |
IHC | 1:200-1:1,000 |
WB | 1:500-1:2,000 |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Cellular response to gamma radiation Source: MGI
Lens development in camera-type eye Source: Ensembl
Microtubule polymerization or depolymerization Source: Ensembl
Multicellular organism aging Source: Ensembl
Muscle contraction Source: ProtInc
Muscle organ development Source: Ensembl
Negative regulation of amyloid fibril formation Source: ARUK-UCL
Negative regulation of apoptotic process Source: HGNC-UCL
Negative regulation of cell growth Source: Ensembl
Negative regulation of cysteine-type endopeptidase activity involved in apoptotic process Source: Ensembl
Negative regulation of gene expression Source: Ensembl
Negative regulation of intracellular transport Source: HGNC-UCL
Negative regulation of protein-containing complex assembly Source: ARUK-UCL
Negative regulation of reactive oxygen species metabolic process Source: Ensembl
Negative regulation of transcription, DNA-templated Source: UniProtKB
Protein folding Source: ProtInc
Protein stabilization Source: CAFA
Regulation of cell death Source: MGI
Regulation of cellular response to heat Source: Reactome
Response to estradiol Source: Ensembl
Response to hydrogen peroxide Source: Ensembl
Response to hypoxia Source: Ensembl
Stress-activated MAPK cascade Source: Ensembl
Tubulin complex assembly Source: Ensembl
A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM2 is characterized by weakness of the proximal and distal limb muscles, weakness of the neck, velopharynx and trunk muscles, hypertrophic cardiomyopathy, and cataract in a subset of patients.
Cataract 16, multiple types (CTRCT16):
An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT16 includes posterior polar cataract, among others. Posterior polar cataract is a subcapsular opacity, usually disk-shaped, located at the back of the lens.
CRYAB mutations may be involved in restrictive cardiomyopathy (RCM), a rare non-ischemic myocardial disease. RCM is characterized by restrictive ventricular-filling physiology in the presence of normal or reduced diastolic and/or systolic volumes (of 1 or both ventricles), biatrial enlargement, and normal ventricular wall thickness.
Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related (MFMFIH-CRYAB):
A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFMFIH-CRYAB has onset in the first weeks of life after a normal neonatal period. Affected infants show rapidly progressive muscular rigidity of the trunk and limbs associated with increasing respiratory difficulty resulting in death before age 3 years.
Cardiomyopathy, dilated 1II (CMD1II):
A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols
Related Products
Mouse Anti-CRYAB Recombinant Antibody (CBXC-2242) (CAT#: V2LY-1206-LY1306)
Mouse Anti-CRYAB Recombinant Antibody (4E8-1C5) (CAT#: V2LY-1206-LY1296)
Mouse Anti-CRYAB Recombinant Antibody (1A10-1A4) (CAT#: V2LY-1206-LY1295)
Rabbit Anti-CRYAB Recombinant Antibody (CBXC-2851) (CAT#: V2LY-1206-LY1309)
Mouse Anti-CRYAB Recombinant Antibody (CBT3874) (CAT#: V2LY-0625-LY2159)
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CAT#: CBMAB-A4345-YC)
Mouse Anti-CRYAB Monoclonal Antibody (0937) (CAT#: V2LY-1206-LY1291)
Mouse Anti-CRYAB Recombinant Antibody (2E8) (CAT#: V2LY-1206-LY1292)
Mouse Anti-CRYAB Recombinant Antibody (CBFYC-2249) (CAT#: V2LY-1206-LY1300)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
